BMJ:前驱糖尿病与心血管疾病风险

2020-07-18 MedSci原创 MedSci原创

结果表明,在一般人群和动脉粥样硬化性心血管疾病患者中,前驱糖尿病均与全因死亡率和心血管疾病的风险增加有关。 筛查和适当的前驱糖尿病管理可能有助于心血管疾病的一级和二级预防

近日研究人员考察了对于一般人群和动脉粥样硬化性血管疾病病史患者中,前驱糖尿病与全因死亡率和突发心血管疾病风险之间的关系。
 
本次研究为系统综述和荟萃分析,收集截至2020年4月25日的相关资料,包含前瞻性队列研究或临床试验的事后分析,考察前驱糖尿病患者的所有原因死亡率或心血管疾病调整后相对风险。主要结果为全因死亡率和复合性心血管疾病。次要结果是冠心病和中风的风险。
 
共纳入129项研究,总计10069955名参与者。在一般人群中,前驱糖尿病与全因死亡率(相对风险1.13)、复合心血管疾病(1.15)、冠心病(1.16)和中风(1.14)的风险增加相关,中位随访时间为9.8年。与正常血糖参与者相比,前驱糖尿病人群的全因死亡率、复合性心血管疾病、冠心病和中风的绝对风险差异分别为7.36/10000人-年、8.75/10000人-年、6.59/10000人-年和3.68/10000人-年。糖耐量异常人群比空腹血糖异常人群具有更高的全因死亡率、冠心病和中风的风险。在动脉粥样硬化性心血管疾病患者中,前驱糖尿病与全因死亡率(相对危险度1.36,)、复合性心血管疾病(1.37)和冠心病(1.15)的风险增加相关,中位随访时间为3.2年,但中风风险无显著性差异(1.05)。与正常血糖相比,前驱糖尿病伴动脉粥样硬化性心血管疾病患者的全因死亡率、复合性心血管疾病、冠状动脉疾病和中风的绝对风险差别分别为66.19/10000人-年、189.77/10000人-年、40.62/10000人-年和8.54/10000人-年。
 
结果表明,在一般人群和动脉粥样硬化性心血管疾病患者中,前驱糖尿病均与全因死亡率和心血管疾病的风险增加有关。 筛查和适当的前驱糖尿病管理可能有助于心血管疾病的一级和二级预防
 
原始出处:
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2021-04-22 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2020-08-07 咻凡

    学到了!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2020-07-19 wangzheng00

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1849058, encodeId=1d8f18490588d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 22 09:00:13 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806731, encodeId=6d72806e312b, content=学到了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:43:41 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473242, encodeId=762214e3242ed, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498753, encodeId=b5371498e53ff, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jul 20 00:00:13 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803314, encodeId=051e80331462, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQpmzBtwg9CW7YicibuHSzMIfhBANYvGZiaEcH2gk0IrjXgRzR231rEUtXkHIBBbvbe6Zw/132, createdBy=80725261937, createdName=wangzheng00, createdTime=Sun Jul 19 14:54:04 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043221, encodeId=862210432218b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jul 18 12:00:13 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2020-07-18 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Gastroenterology:泮托拉唑可预防接受利伐沙班和/或阿司匹林患者的胃十二指肠事件

抗血小板和抗凝剂与上消化道出血增加有关。本研究中,我们评估了质子泵抑制剂治疗是否可以降低这种风险。

Circulation:减少支链氨基酸摄入可降低代谢综合征相关血栓形成风险

支链氨基酸(BCAAs)是必需的营养素,包括亮氨酸、异亮氨酸和缬氨酸,可作为能量生成的原料以及重要营养素和代谢信号的调节剂。近期研究表明,BCAA分解代谢功能障碍与心血管疾病的风险有关。

Diabetes Care:hs-cTnT和NT-proBNP与1型糖尿病患者心血管疾病的关系

在T1D患者中,hs-cTnT和NT-proBNP的浓度和预测能力存在性别差异。总体而言,将其添加到传统危险因素模型中不会增加CVD和MACE的曲线下面积。

Lancet子刊:来自21个国家157436人的研究表明,空气污染是导致心血管疾病的主要因素

目前,我国心血管疾病的人数与日俱增,据2019年的报道,我国全部心血管相关疾病人数有3.3亿,其中冠心病有1100万。

J Urol:GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率

雄激素剥夺疗法可能会增加患心血管疾病的风险。有限的数据表明,与GnRH激动剂相比,GnRH(促性腺激素释放激素)拮抗剂可能会降低心血管疾病的风险。

The Lancet Planetary Health:来自21个国家157436人的国际研究表明,空气污染是导致心血管疾病的主要因素

俄勒冈州立大学(Oregon State University)的一项新研究发现,从低收入国家到高收入国家,长期暴露于室外空气中的细颗粒物污染是导致心血管疾病和死亡的主要因素。